Evidence map›Paper›PMID 36711524›Full record

ArticlebioRxiv : the preprint server for biology2023

Defining T cell receptor repertoires using nanovial-based affinity and functional screening.

Doyeon Koo, Zhiyuan Mao, Robert Dimatteo, Natalie Tsubamoto, Miyako Noguchi, Jami McLaughlin, Wendy Tran, Sohyung Lee, Donghui Cheng, Joseph de Rutte and 3 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Doyeon KooDepartment of Bioengineering, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Zhiyuan MaoDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Robert DimatteoDepartment of Chemical and Biomolecular Engineering, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Natalie TsubamotoDepartment of Bioengineering, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Miyako NoguchiDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Jami McLaughlinDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Wendy TranDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Sohyung LeeDepartment of Chemical and Biomolecular Engineering, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Donghui ChengEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Joseph de RutteDepartment of Bioengineering, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Giselle Burton SojoDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Owen N WitteDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Dino Di CarloDepartment of Bioengineering, University of California, Los Angeles; Los Angeles, CA 90095, USA.
University of California, Los Angeles · USCalifornia NanoSystems Institute · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Lab on a particle technology for functional screening of therapeutic cellsR21CA256084 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DI CARLO, DINO · 2021 to 2022
$510k
NCI NIH HHS P30 CA016042NCI NIH HHS R21 CA256084
6 · The paper itself

Abstract

The ability to selectively bind to antigenic peptides and secrete cytokines can define populations of cells with therapeutic potential in emerging T cell receptor (TCR) immunotherapies. We leverage cavity-containing hydrogel microparticles, called nanovials, each coated with millions of peptide-major histocompatibility complex (pMHC) monomers to isolate antigen-reactive T cells. T cells are captured and activated by pMHCs and secrete cytokines on nanovials, allowing sorting based on both affinity and function. The TCRs of sorted cells on nanovials are sequenced, recovering paired αβ-chains using microfluidic emulsion-based single-cell sequencing. By labeling nanovials having different pMHCs with unique oligonucleotide-barcodes we could link TCR sequence to targets with 100% accuracy. We identified with high specificity an expanded repertoire of functional TCRs targeting viral antigens compared to standard techniques.

Identifiers

PMID36711524
PMCPMC9882161
OpenAlexW4317555794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.